FibroBiologics (FBLG) Other Non-Current Liabilities (2022 - 2024)
FibroBiologics (FBLG) posted quarterly Other Non-Current Liabilities of $2.9 million for Q3 2024, down 40.03% on a QoQ basis from $4.8 million in Q2 2024.
FibroBiologics (FBLG) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends
FibroBiologics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $2.9 million in Q3 2024.
- Other Non-Current Liabilities for Q3 2024 came in at $2.9 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $2.9 million (changed N/A YoY), and the FY2023 annual result was $2573.0, down 99.9% from the prior year.
- Other Non-Current Liabilities eased to $2.9 million in Q3 2024, from $4.8 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $4.8 million in Q2 2024 and troughed at $2573.0 in Q4 2023.
- A 3-year average of $2.2 million and a median of $2.6 million in 2022 frame the typical range for Other Non-Current Liabilities.
- The widest annual swing landed in 2023, when Other Non-Current Liabilities slumped 99.9%; it then jumped 87.1% in 2024.
- A 3-year view of Other Non-Current Liabilities shows it stood at $2.6 million in 2022, then slumped by 99.9% to $2573.0 in 2023, then soared by 112103.65% to $2.9 million in 2024.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $2.9 million in Q3 2024, $4.8 million in Q2 2024, and $2573.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 4.81 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 463,000.00 |
| Dec 31, 2022 | 2.57 Mn |